A Delluc, E Pasquier, L de Saint Martin and D Mottier (2006) “Rituximab’s cost for the treatment of primary cold agglutinin disease should not limit its use”, Haematologica. Pavia, Italy, 91(3), pp. ECR05-ECR05. doi: 10.3324/%x.